Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03097068
Recruitment Status : Unknown
Verified May 2017 by Louis C. Glazer, MD, Vitreo-Retinal Associates, Michigan. Recruitment status was: Recruiting
First Posted : March 31, 2017
Last Update Posted : May 9, 2017
Louis C. Glazer, MD
Michigan State University
Information provided by (Responsible Party):
Louis C. Glazer, MD, Vitreo-Retinal Associates, Michigan
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Condition or disease
Diabetic Macular Edema
Lucentis injections are the current standard of care for diabetic macular edema. The only deviation from the standard of care in the current protocol is an aqueous tap before the first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of diabetes mellitus
Best corrected visual acuity 20/32 - 20/320
Diabetic macular edema involving the center of the macula
Optical coherence tomography central subfield thickness of at least 250 microns
History of anti-vascular endothelial growth factor treatment in the past 12 months
Any diabetic macular edema treatment in the past 4 months
Heart attack, stroke, transient ischemic attack or acute congestive heart failure within 4 months